Novartis suffers a loss in its fight to block Regenxbio's Zolgensma patent extension
Novartis came up short on Wednesday in its bid to block its tiny biotech partner Regenxbio from getting a patent term extension (PTE) on Zolgensma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
